Pharmacogenetics of proliferation signal inhibitors (mTOR inhibitors) in renal transplantation

被引：0
|
作者：
不详
机构：
来源：
PHARMACOGENOMICS | 2012年 / 13卷 / 15期
关键词：
SIROLIMUS; EFFICACY;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：1680 / 1681
页数：2
相关论文
共 50 条
  • [21] Withdrawal of proliferation signal inhibitors due to adverse events in the maintenance phase of heart transplantation
    Gonzalez-Vilchez, Francisco
    Antonio Vazquez de Prada, Jose
    Almenar, Luis
    Maria Arizon del Prado, Jose
    Mirabet, Sonia
    Diaz-Molina, Beatriz
    Francisco Delgado, Juan
    Gomez-Bueno, Manuel
    Jesus Paniagua, Maria
    Perez-Villa, Felix
    Roig, Eulalia
    Martinez-Dolz, Luis
    Brossa, Vicens
    Luis Lambert, Jose
    Segovia, Javier
    Generosa Crespo-Leiro, Maria
    Jesus Ruiz-Cano, Maria
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2012, 31 (03) : 288 - 295
  • [22] Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
    Kranz, Birgitta
    Wingen, Anne-Margret
    Vester, Udo
    Koenig, Jens
    Hoyer, Peter F.
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1293 - 1298
  • [23] Long-term side effects of treatment with mTOR inhibitors in children after renal transplantation
    Birgitta Kranz
    Anne-Margret Wingen
    Udo Vester
    Jens König
    Peter F. Hoyer
    Pediatric Nephrology, 2013, 28 : 1293 - 1298
  • [24] mTOR inhibitors
    Hantraye, Benedicte
    Clere, Nicolas
    ACTUALITES PHARMACEUTIQUES, 2015, 54 (551): : 28 - 29
  • [25] Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation
    Asante-Korang, Alfred
    Carapellucci, Jennifer
    Krasnopero, Diane
    Doyle, Abigail
    Brown, Brian
    Amankwah, Ernest
    CLINICAL TRANSPLANTATION, 2017, 31 (10)
  • [26] Benefits of proliferation signal inhibitors beyond immunosuppression. Vascular protection and experience in heart transplantation
    Caillard, S.
    NEPHROLOGIE & THERAPEUTIQUE, 2009, 5 : S379 - S384
  • [27] Conversion to Proliferation Signal Inhibitors-Based Immunosuppressive Regimen in Kidney Transplantation: To Whom and When?
    Sahin, S.
    Gurkan, A.
    Uyar, M.
    Dheir, H.
    Turunc, V.
    Varilsuha, C.
    Kacar, S.
    TRANSPLANTATION PROCEEDINGS, 2011, 43 (03) : 837 - 840
  • [28] Temporal Trends in the Use of Proliferation Signal Inhibitors in Maintenance Heart Transplantation: A Spanish Multicenter Study
    Gonzalez-Vilchez, F.
    Almenar, L.
    Arizon, J. M.
    Mirabet, S.
    Delgado, J. F.
    Diez de Molina, B.
    Gomez, M.
    Paniagua, M. J.
    Perez-Villa, F.
    Roig, E.
    Vazquez de Prada, J. A.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (08) : 2997 - 3000
  • [29] Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors
    Nashan, B
    TRANSPLANT INTERNATIONAL, 2004, 17 (06) : 279 - 285
  • [30] Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation
    Isakova, T.
    Xie, H.
    Messinger, S.
    Cortazar, F.
    Scialla, J. J.
    Guerra, G.
    Contreras, G.
    Roth, D.
    Burke, G. W., III
    Molnar, M. Z.
    Mucsi, I.
    Wolf, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (01) : 100 - 110
12345